A phase II study of twice-daily (BID) cytarabine (A) and fludarabine (F) and gentuzumab ozogamycin (GO) in patients (pts) with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
H. Ghanem
No relevant relationships to disclose
H. Kantarjian
No relevant relationships to disclose
G. Garcia-Manero
No relevant relationships to disclose
F. Ravandi
No relevant relationships to disclose
S. Faderl
No relevant relationships to disclose
J. E. Cortes
No relevant relationships to disclose
A. Reyes
No relevant relationships to disclose
S. M. O'Brien
No relevant relationships to disclose
G. Borthakur
No relevant relationships to disclose
T. M. Kadia
No relevant relationships to disclose
J. A. Burger
No relevant relationships to disclose
M. Konopleva
No relevant relationships to disclose
E. Jabbour
No relevant relationships to disclose